Cell2Cure
  • Home
  • The Company
  • Research, Technology and IP
    • Background
  • Clinical
  • Investor and Partners
  • News
  • Contact us
Select Page

The Cell2Cure core technology has been granted patent rights in Australia

by Backoffice | Aug 21, 2022 | Patents

As of the 24th of March 2022, the patent secures C2Cs technological concept for industrial production, upscaling, and distribution of ASC products in Australia (Patent number: 2016342387). The patent “STEM CELL THERAPY BASED ON ADIPOSE-DERIVED STEM CELLS” has...

Recent Posts

  • The Danish Medicines Agency has approved the phase I clinical trial with cell treatment of children with autism and leaky gut syndrome
  • Ethical approval for the ASC phase I clinical trial in children with autism and leaky gut syndrome
  • Cell2Cure has received approval from the Danish Medicinal Agency for a clinical Phase I study
  • The Cell2Cure core technology has been granted patent rights in Australia
  • Patient enrollment finalized in the Phase II trial testing ASC in Sjögren’s syndrome

Recent Comments

    Archives

    • November 2022
    • September 2022
    • August 2022
    • June 2022
    • April 2022
    • February 2022
    • July 2021
    • February 2021
    • January 2021
    • November 2020
    • October 2020
    • January 2020

    Categories

    • Collaborations
    • Patents
    • Studies and testing
    • Trial results

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    © 2021 Cell2Cure | CVR.no 39401975 | Designed by ICR-Design ApS